Shiatsu for amyloidosis symptoms and quality of life
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests whether shiatsu (a gentle Japanese touch therapy) can improve symptoms and quality of life for people with amyloidosis. If you have a bothersome symptom like pain, shortness of breath, or anxiety, this trial may help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of amyloidosis: either Transthyretin (genetic or wild-type) or Light Chain (AL).
- You have at least one bothersome symptom (like pain, shortness of breath, nausea, stomach issues, anxiety, or depression) that you rate as a 3 or higher out of 10.
- You have not had shiatsu before.
- You don't have severe dizziness when standing up (orthostatic hypotension) or fragile skin with blisters.
- You can sit upright and travel to the hospital on your own.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
This study tests a personalized exercise program for people with cardiac amyloidosis to see how it affects their heart and daily life. The goal is to help you feel better and stay active safely.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.